Ibrutinib has revolutionized the treatment of B-cell malignancies since its approval for chronic lymphocytic leukemia. It is also used in mantle cell lymphoma, diffuse large B-cell lymphoma, Waldenstrom’s macroglobulinemia, among others. It is a Bruton’s tyrosine kinase inhibitor that acts on B-cell receptor signaling pathway and predisposes to various infections due to its effects on neutrophils, monocytes and T cells. We present a case of cerebral invasive aspergillosis in a patient being treated with ibrutinib for relapsed chronic lymphocytic leukemia. It was hard to associate the condition to ibrutinib versus the chronic lymphocytic leukemia. The patient was successfully treated with a combination of voriconazole and micafungin, resulting in complete recovery and no residual deficits. This highlights the importance of recognizing the rare complication in those on ibrutinib and initiating the treatment immediately with appropriate antifungal agents to improve prognosis of this potentially fatal condition.
Chanan-KhanACramerPDemirkanFet al.Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol2016; 17: 200–211.
2.
ByrdJCFurmanRRCoutreSEet al.Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med2013; 369: 32–42.
3.
BurgerJATedeschiABarrPMet al.Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med2015; 373: 2425–2437.
4.
DavidsMSBrownJR. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol2014; 10: 957–967.
5.
PalmaMKokhaeiPLundinJet al.The biology and treatment of chronic lymphocytic leukemia. Ann Oncol2006; 17: x144–x154.
6.
BoukhiarM-ARogerCTranJet al.Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma. Exp Hematol Oncol2013; 2: 4–4.
7.
ZhengXDingNSongYet al.Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment. Cancer cell Int2014; 14: 32–32.
8.
MauraFCutronaGFabrisSet al.Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. PloS One2011; 6: e24313–e24313.
9.
DubovskyJABeckwithKANatarajanGet al.Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood2013; 122: 2539–2549.
10.
VarugheseTTaurYCohenNet al.Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis2018. DOI: 10.1093/cid/ciy175 (accessed 3 July 2018).
11.
OkamotoKProiaLADemaraisPL. Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib. Case Rep Infect Dis2016; 2016: 4642831–4642831.
12.
Messina JA, Maziarz EK, Spec A, et al. Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib. In: Open forum infectious diseases. Oxford University Press, 2017; 4: ofw261. DOI: 10.1093/ofid/ofw261.
13.
WangMLBlumKAMartinPet al.Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood2015; 126: 739–745.
14.
AhnIEJerussiTFarooquiMet al.Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood2016; 128: 1940–1943. DOI: 10.1182/blood-2016-06-722991 ((accessed 8 October 2016).
15.
LionakisMSDunleavyKRoschewskiMet al.Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell2017; 31: 833–843. e835).
16.
ChamilosGLionakisMSKontoyiannisDP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis2017; 66: 140–148.
17.
GhezDCallejaAProtinCet al.Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood2018; 131: 1955–1959.
18.
SunCTianXLeeYSet al.Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood2015; 126: 2213–2219.
19.
OchsHDSmithC. X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine1996; 75: 287–299.
20.
LionakisMSNeteaMGHollandSM. Mendelian genetics of human susceptibility to fungal infection. Cold Spring Harbor Perspect Med2014; 4: a019638–a019638.
21.
RieberNGazendamRPFreemanAFet al.Extrapulmonary Aspergillus infection in patients with CARD9 deficiency. JCI Insight2016; 1(17): e89890–e89890. DOI: 10.1172/jci.insight.89890.
22.
LionakisMSKontoyiannisDP. Glucocorticoids and invasive fungal infections. Lancet2003; 362: 1828–1838.
HerbstSShahAMoyaMMet al.Phagocytosis-dependent activation of a TLR9–BTK–calcineurin–NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus. EMBO Mol Med2015; 7: 240–258.
25.
Sagiv-BarfiIKohrtHECzerwinskiDKet al.Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci2015; 112: E966–E972.
26.
MarrKASchlammHTHerbrechtRet al.Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med2015; 162: 81–89.
27.
PattersonTFThompsonGR IIIDenningDWet al.Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis2016; 63: e1–e60.
28.
CordonnierCMaurySPautasCet al.Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant2004; 33: 943–943.
29.
SchwartzSThielE. Cerebral aspergillosis: tissue penetration is the key. Med Mycol2009; 47: S387–S393.
30.
SchwartzSRuhnkeMRibaudPet al.Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood2005; 106: 2641–2645.
